What is your preferred second line regimen for follicular lymphoma that has relapsed four years out since receiving BR?

Many possible answers here, but I have been using zanubrutinib + obino in this setting as in the ROSEWOOD study. Zinzani et al., PMID 37506346

While not compared directly to rituximab + rev, it certainly looks better. Don’t want to repeat benda and impair T cell function for future CAR-T or bispecif...

I try to move away from chemotherapy in FL in the relapse setting, especially with the available options and CAR-T in particular. I would consider lenalidomide-rituximab in second line and zanubrutinib - obinutuzumab in 3L. Obinutuzumab seems to be a better CD20 antibody for RR so lenalidomide and o...